ECTRIMS eLearning

Demographics, lifestyle risk factors, and health outcomes of two large international samples of people with multiple sclerosis: HOLISM Longitudinal and Validation cohorts
Author(s): ,
T. Weiland
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
A. De Livera
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
C. Brown
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
G. Jelinek
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
Z. Aitken
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
S. Simpson, Jr.
Affiliations:
School of Population & Global Health | Neuroepidemiology Unit, University of Melbourne, Carlton, VIC; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
,
S. Neate
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
K. Taylor
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
E. O`Kearney
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
,
W. Bevens
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
C. Marck
Affiliations:
Melbourne School of Population and Global Health, The University of Melbourne
ECTRIMS Learn. Simpson, Jr. S. 10/11/18; 228530; P686
Steve Simpson, Jr.
Steve Simpson, Jr.
Contributions
Abstract

Abstract: P686

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Epidemiology

Objective: To report findings from the Health Outcomes and Lifestyle In a Sample of people with Multiple sclerosis (HOLISM) Longitudinal and Validation Cohorts. Here we report (1) participation, sociodemographics, disease characteristics, medication use, modifiable lifestyle risk factor exposures, and health outcomes of the HOLISM Longitudinal Cohort at 2.5-years post enrolment; (2) attrition at this 2.5-year wave; and (3) characteristics of the independent HOLISM Validation cohort.
Methods: For the HOLISM Longitudinal study, people with multiple sclerosis (MS) recruited at baseline through web 2.0 platforms were contacted 2.5-years later for follow-up. Participants completed a comprehensive, online questionnaire of their sociodemographics, modifiable lifestyle exposures, and health outcome measures using validated and researcher-derived tools. The same recruitment process was used to collect comprehensive data for the HOLISM Validation cohort.
Results: Of 2,466 people with MS at baseline, 1,401 (56.8%) provided data at 2.5-year follow-up. Completion of the 2.5-year wave was associated with higher baseline levels of educational attainment, healthier lifestyle, and better health outcomes. These participants were of diverse geographical location, were majority female, married, and unemployed/retired. Nearly 40% were overweight/obese, most were physically active, non-smokers, consumed low amounts of alcohol, used vitamin D and/or at least one form of omega-3 fatty acid supplements. 42% reported current disease-modifying drug use. As measured by Patient Disease Steps Scale, 30% reported cane or gait disability, while 13% relied on major mobility supports. Approximately half the respondents reported a comorbidity, 63% screened positive for clinically significant fatigue by Fatigue Severity Scale, and 22% screened positive for depression by Patient Health Questionnaire-9, while 5% reported moderate to total visual impairment. The HOLISM Validation cohort characteristics were in line with previously reported HOLISM baseline data.
Conclusions: These international samples provide platforms to explore how changes in modifiable environmental/behavioural risk factor exposures over time are associated with health outcomes in people with MS.
Disclosure: The study was funded by the Bloom Foundation, Wal Pisciotta, and the Horne Family Charitable Trust. CM is funded by an Early Career Fellowship from the National Health and Medical Research Council (ID 1120014).
TJW: nothing to disclose.
AMDL: nothing to disclose.
CRB: nothing to disclose.
GAJ receives royalties for his books, Overcoming Multiple Sclerosis and Recovering from Multiple Sclerosis, and has received remuneration for conducting lifestyle educational workshops for people with MS.
ZA: nothing to disclose.
SSJ: nothing to disclose.
SN has received remuneration for conducting lifestyle educational workshops for people with MS.
KLT has received remuneration for conducting lifestyle educational workshops for people with MS.
EO´K: nothing to disclose.
WB: nothing to disclose.
CM: nothing to disclose.

Abstract: P686

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Epidemiology

Objective: To report findings from the Health Outcomes and Lifestyle In a Sample of people with Multiple sclerosis (HOLISM) Longitudinal and Validation Cohorts. Here we report (1) participation, sociodemographics, disease characteristics, medication use, modifiable lifestyle risk factor exposures, and health outcomes of the HOLISM Longitudinal Cohort at 2.5-years post enrolment; (2) attrition at this 2.5-year wave; and (3) characteristics of the independent HOLISM Validation cohort.
Methods: For the HOLISM Longitudinal study, people with multiple sclerosis (MS) recruited at baseline through web 2.0 platforms were contacted 2.5-years later for follow-up. Participants completed a comprehensive, online questionnaire of their sociodemographics, modifiable lifestyle exposures, and health outcome measures using validated and researcher-derived tools. The same recruitment process was used to collect comprehensive data for the HOLISM Validation cohort.
Results: Of 2,466 people with MS at baseline, 1,401 (56.8%) provided data at 2.5-year follow-up. Completion of the 2.5-year wave was associated with higher baseline levels of educational attainment, healthier lifestyle, and better health outcomes. These participants were of diverse geographical location, were majority female, married, and unemployed/retired. Nearly 40% were overweight/obese, most were physically active, non-smokers, consumed low amounts of alcohol, used vitamin D and/or at least one form of omega-3 fatty acid supplements. 42% reported current disease-modifying drug use. As measured by Patient Disease Steps Scale, 30% reported cane or gait disability, while 13% relied on major mobility supports. Approximately half the respondents reported a comorbidity, 63% screened positive for clinically significant fatigue by Fatigue Severity Scale, and 22% screened positive for depression by Patient Health Questionnaire-9, while 5% reported moderate to total visual impairment. The HOLISM Validation cohort characteristics were in line with previously reported HOLISM baseline data.
Conclusions: These international samples provide platforms to explore how changes in modifiable environmental/behavioural risk factor exposures over time are associated with health outcomes in people with MS.
Disclosure: The study was funded by the Bloom Foundation, Wal Pisciotta, and the Horne Family Charitable Trust. CM is funded by an Early Career Fellowship from the National Health and Medical Research Council (ID 1120014).
TJW: nothing to disclose.
AMDL: nothing to disclose.
CRB: nothing to disclose.
GAJ receives royalties for his books, Overcoming Multiple Sclerosis and Recovering from Multiple Sclerosis, and has received remuneration for conducting lifestyle educational workshops for people with MS.
ZA: nothing to disclose.
SSJ: nothing to disclose.
SN has received remuneration for conducting lifestyle educational workshops for people with MS.
KLT has received remuneration for conducting lifestyle educational workshops for people with MS.
EO´K: nothing to disclose.
WB: nothing to disclose.
CM: nothing to disclose.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies